Member Info for Hurst10

US buyers stepping in as everything else is crashing!
Expect size buyers to carry on during the week and they will eventually find it very difficult to get size!!

M&A activity is about to take off again, with results season having produced very strong numbers, look at Pfizer!
Avacta being “ un canard assis”, will soon feature with more updates from the AVA6000 trials and the majors will all be having their morning coffees near 203 Fulham Rd. (The Royal Marsden Hospital), to get hold of Avacta’s management.
Will be an interesting couple of weeks!

Lunch time indeed.
S&P futures will be followed.

Just pointing out that AVA6000 might qualify for consideration by the FDA.
Never mind, we have two exciting months ahead and potentially a new trading range.
17.00! That time again, marvellous. ??
Have a good bank Holliday week end.

Worth remembering, ref AVA6000
“FDA will respond to breakthrough therapy designation requests within 60 days of receipt of the request.”

Look buy / sell ratio post US hours

Merck Non-GAAP EPS of $2.14 beats by $0.31, revenue of $15.9B beats by $1.26B
More M&A.

Ref M&A, companies like Avacta will and are attracting the attention from some of the majors like Novartis, as they recognise the groundbreaking advancements being made by companies like Avacta in their Therapeutics division,Gene therapy etc.
Novartis’ CEO during yesterday’s Q1 2022 Results-Earnings Call transcript:
So we continue to look. Our focus remains, as I've guided in recent quarters, into the sub $2 billion space to see if there are attractive methods. And when there are good deals out there, we're, of course, looking to do them. I do think over the course of this year as well, expectations amongst sellers, so to speak, will adjust. And there may be more openness to think about how partnerships and M&A and business development could be conducted. So there could be more activity certainly in the sector second half of the year. And we'll, of course, be doing our part to diligently keep screening and see what's out there that could be attractive. Thanks, Kerry. Next, question, operator.

188/ purchase post market print

Novartis results webinar later today, expect them to spend time on radiotherapy and Oncology
The company has made it very clear, they are out there and are ready to go shopping.

We now have NY waking up and renewed buying will appear.
Look at Novartis Q1 results, stock moving higher.
:Novartis Q1 sales rise on the back of Sandoz unit, confirms FY22 outlook; hires analyst to drive growth/strategy.
I would expect Novartis to continue to expand in the Radioligand therapy,Gene and Cell therapy area.

Yep
Latest addition to the board, worked also at Novartis!

Just watch Novartis, Astra Zeneca, Merck etc shopping in the ground breaking area of Bio tech ie. Avacta.
Look at the changes and closures Novartis are making and have made, they have realised the sector is changing fast!!
The sector have plenty of cash, last est. north of a trillion $.
Exciting quarter ahead for Avacta!
Make a proper SOP of the company in May , post more news update from the company.
Index funds overseas will have to buy the stock again!!!

With yet another Korean commitment/grant/investment AffyXell Therapeutics are motoring. Next generation Exosomes are taking centre stage and growing fast.
The global exosomes market size is expected to reach USD 2.28 billion by 2030, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 18.8% during the forecast period.
Moreover, an increase in funding for R&D in this field is poised to positively influence industrial growth. Rise in funding capacity by public and private institutions is indicative of the importance of exRNA molecules across the community engaged in translational research pertaining to diagnostics and therapeutic product development.
This could be huge for Affyxell and Avacta. We saw Samsung Ventures etc investing further this year in Affyxell and perhaps more to come.

85/ just picked up at 41’
Good morning NY

Post market buy prints coming up!
Bring on Friday

We will end up with another up day.
Post market buy prints and off course
Interesting day ahead and Friday!
M&A picking up fast in the US post AACR.

8 choice

20min left and it is early rise(06.00) in NY and the buying will start again.
Event couple of weeks ahead!!!

Watch opening price 138-40
145-50 pre US opening.
Gents, you really need to understand AVA6000 will be much bigger than Covid, good luck to everybody and we have plenty of size buyers, so any decent sellers out there, please come forward!!
Novartis, Astra Zeneca and Hoffmann La Roche are all ready.
Stand by for surprise entry!!